What is Insmed's D&A?

Insmed (INSM) reported D&A of $2.93M in Q1 2026.

How has Insmed's D&A changed year-over-year?

Insmed's D&A increased by 55.8% year-over-year, from $1.88M to $2.93M.

What is the long-term trend for Insmed's D&A?

Over 4 years (2021 to 2025), Insmed's D&A has grown at a 3.4% compound annual growth rate (CAGR), from $9.13M to $10.45M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Insmed INSM D&A

D&A at other companies

Sarepta Therapeutics, Inc.SRPT

$10.59M+6.2%

United TherapeuticsUTHR

$22.6M+14.1%

Solid Biosciences Inc.SLDB

$395K-2.9%

ANI PharmaceuticalsANIP

$20.92M-8.6%

Regeneron PharmaceuticalsREGN

$123.2M-2.9%

SavaraSVRA

$24K-20.0%

Other financials

Income statement

See full

Revenue$306.0M+230%

Gross profit$258.5M+261%

Operating income-$153.3M+38.2%

Net income-$163.6M+36.3%

EPS (diluted)-$0.76+46.5%

Balance sheet

See full

Cash & equivalents$582.2M+44.4%

Total debt$580.3M-49.2%

Total equity$704.9M+611%

Total assets$2.1B+15.2%

Cash flow

See full

Operating cash flow-$222.7M+15.0%

CapEx$3.5M-65.4%

Free cash flow-$226.2M+16.9%

Valuation

See full

Market cap$23.11B+17.6%

Enterprise value$23.11B+22.0%

P/S28.2×-21.1×

Profitability

See full

Gross margin81.8%+5.3pp

Operating margin-140.6%-43.9pp

Net margin-144.4%-45.3pp

FCF margin-112.5%-35.3pp

Returns & leverage

See full

Return on equity-294.5%—

Debt / equity0.8×-10.7×

Current ratio4.5×-1.4×

Where this comes from

Reported directly by Insmed in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Insmed’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insmed's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Insmed's D&A?: Insmed (INSM) reported D&A of $2.93M in Q1 2026.
How has Insmed's D&A changed year-over-year?: Insmed's D&A increased by 55.8% year-over-year, from $1.88M to $2.93M.
What is the long-term trend for Insmed's D&A?: Over 4 years (2021 to 2025), Insmed's D&A has grown at a 3.4% compound annual growth rate (CAGR), from $9.13M to $10.45M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.